Depression of cardiac function by bisantrene

M. Artman, J. S. Roloff, R. D. Olson, Mark D Parrish

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Bisantrene is a newer anthracycline derivative currently being investigated in phase 2 trials. One presumed advantage of bisantrene is that it is purportedly free of cardiotoxic effects. However, bisantrene apparently precipitated congestive heart failure after a single intravenous infusion in a young boy, prompting our study of a second child who remained asymptomatic but had transient declines in cardiac function after receiving bisantrene. Since bisantrene may acutely depress myocardial contractile function, further investigation is necessary.

Original languageEnglish (US)
Pages (from-to)1517-1518
Number of pages2
JournalSouthern Medical Journal
Volume78
Issue number12
StatePublished - 1985
Externally publishedYes

Fingerprint

bisantrene
Anthracyclines
Intravenous Infusions
Heart Failure

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Artman, M., Roloff, J. S., Olson, R. D., & Parrish, M. D. (1985). Depression of cardiac function by bisantrene. Southern Medical Journal, 78(12), 1517-1518.

Depression of cardiac function by bisantrene. / Artman, M.; Roloff, J. S.; Olson, R. D.; Parrish, Mark D.

In: Southern Medical Journal, Vol. 78, No. 12, 1985, p. 1517-1518.

Research output: Contribution to journalArticle

Artman, M, Roloff, JS, Olson, RD & Parrish, MD 1985, 'Depression of cardiac function by bisantrene', Southern Medical Journal, vol. 78, no. 12, pp. 1517-1518.
Artman M, Roloff JS, Olson RD, Parrish MD. Depression of cardiac function by bisantrene. Southern Medical Journal. 1985;78(12):1517-1518.
Artman, M. ; Roloff, J. S. ; Olson, R. D. ; Parrish, Mark D. / Depression of cardiac function by bisantrene. In: Southern Medical Journal. 1985 ; Vol. 78, No. 12. pp. 1517-1518.
@article{a11d0c6e2c4c4aff999d94dabf9c6600,
title = "Depression of cardiac function by bisantrene",
abstract = "Bisantrene is a newer anthracycline derivative currently being investigated in phase 2 trials. One presumed advantage of bisantrene is that it is purportedly free of cardiotoxic effects. However, bisantrene apparently precipitated congestive heart failure after a single intravenous infusion in a young boy, prompting our study of a second child who remained asymptomatic but had transient declines in cardiac function after receiving bisantrene. Since bisantrene may acutely depress myocardial contractile function, further investigation is necessary.",
author = "M. Artman and Roloff, {J. S.} and Olson, {R. D.} and Parrish, {Mark D}",
year = "1985",
language = "English (US)",
volume = "78",
pages = "1517--1518",
journal = "Southern Medical Journal",
issn = "0038-4348",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Depression of cardiac function by bisantrene

AU - Artman, M.

AU - Roloff, J. S.

AU - Olson, R. D.

AU - Parrish, Mark D

PY - 1985

Y1 - 1985

N2 - Bisantrene is a newer anthracycline derivative currently being investigated in phase 2 trials. One presumed advantage of bisantrene is that it is purportedly free of cardiotoxic effects. However, bisantrene apparently precipitated congestive heart failure after a single intravenous infusion in a young boy, prompting our study of a second child who remained asymptomatic but had transient declines in cardiac function after receiving bisantrene. Since bisantrene may acutely depress myocardial contractile function, further investigation is necessary.

AB - Bisantrene is a newer anthracycline derivative currently being investigated in phase 2 trials. One presumed advantage of bisantrene is that it is purportedly free of cardiotoxic effects. However, bisantrene apparently precipitated congestive heart failure after a single intravenous infusion in a young boy, prompting our study of a second child who remained asymptomatic but had transient declines in cardiac function after receiving bisantrene. Since bisantrene may acutely depress myocardial contractile function, further investigation is necessary.

UR - http://www.scopus.com/inward/record.url?scp=0022336522&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022336522&partnerID=8YFLogxK

M3 - Article

C2 - 3865379

AN - SCOPUS:0022336522

VL - 78

SP - 1517

EP - 1518

JO - Southern Medical Journal

JF - Southern Medical Journal

SN - 0038-4348

IS - 12

ER -